Nifty
Sensex
:
:
14677.80
48732.55
-18.70 (-0.13%)
41.75 (0.09%)

Pharmaceuticals & Drugs - API

Rating :
69/99

BSE: 524348 | NSE: AARTIDRUGS

817.50
14-May-2021
  • Open
  • High
  • Low
  • Previous Close
  •  804.00
  •  841.80
  •  796.10
  •  798.30
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1662329
  •  13643.38
  •  1026.95
  •  190.53

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 7,622.36
  • 26.50
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 7,994.07
  • 0.06%
  • 8.01

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 60.20%
  • 0.84%
  • 31.86%
  • FII
  • DII
  • Others
  • 2.99%
  • 1.59%
  • 2.52%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.68
  • 9.64
  • 13.24

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.40
  • 8.11
  • 5.63

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 19.66
  • 15.52
  • 19.77

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.05
  • 16.79
  • 15.56

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.81
  • 3.75
  • 4.03

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 10.79
  • 10.68
  • 11.19

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Net Sales
501.75
449.64
11.59%
530.25
473.51
11.98%
578.11
477.50
21.07%
544.67
405.43
34.34%
Expenses
420.82
378.33
11.23%
424.49
406.02
4.55%
461.67
409.20
12.82%
410.70
350.71
17.11%
EBITDA
80.93
71.31
13.49%
105.76
67.49
56.70%
116.44
68.30
70.48%
133.97
54.72
144.83%
EBIDTM
16.13%
15.86%
19.95%
14.25%
20.14%
14.30%
24.60%
13.50%
Other Income
0.97
0.98
-1.02%
2.00
0.25
700.00%
0.29
0.19
52.63%
1.26
0.06
2,000.00%
Interest
4.37
7.47
-41.50%
4.97
8.39
-40.76%
7.05
8.54
-17.45%
6.57
9.33
-29.58%
Depreciation
12.28
12.49
-1.68%
12.65
12.36
2.35%
12.56
12.09
3.89%
12.38
11.81
4.83%
PBT
65.25
60.71
7.48%
90.36
43.08
109.75%
97.12
47.86
102.93%
116.28
33.64
245.66%
Tax
13.60
1.85
635.14%
22.33
15.30
45.95%
21.85
15.55
40.51%
30.83
11.18
175.76%
PAT
51.65
58.86
-12.25%
68.03
27.78
144.89%
75.27
32.31
132.96%
85.45
22.46
280.45%
PATM
10.29%
13.09%
12.83%
5.87%
13.02%
6.77%
15.69%
5.54%
EPS
5.54
6.32
-12.34%
7.30
2.98
144.97%
8.08
3.47
132.85%
9.17
2.41
280.50%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 11
Mar 10
Mar 09
Mar 08
Net Sales
2,154.78
1,806.09
1,560.94
1,243.63
1,195.17
1,139.84
1,096.88
501.05
478.50
382.12
312.36
Net Sales Growth
19.31%
15.71%
25.51%
4.05%
4.85%
3.92%
118.92%
4.71%
25.22%
22.33%
 
Cost Of Goods Sold
1,321.05
1,127.29
1,013.53
737.72
744.43
735.08
724.24
321.34
301.35
238.85
197.35
Gross Profit
833.73
678.79
547.40
505.91
450.75
404.77
372.65
179.71
177.15
143.27
115.01
GP Margin
38.69%
37.58%
35.07%
40.68%
37.71%
35.51%
33.97%
35.87%
37.02%
37.49%
36.82%
Total Expenditure
1,717.68
1,540.57
1,350.03
1,041.76
1,004.68
960.02
924.51
431.87
396.04
315.67
266.61
Power & Fuel Cost
-
103.83
84.39
71.42
59.42
53.93
49.56
29.07
26.48
23.27
19.70
% Of Sales
-
5.75%
5.41%
5.74%
4.97%
4.73%
4.52%
5.80%
5.53%
6.09%
6.31%
Employee Cost
-
61.35
54.55
52.14
47.95
40.19
33.26
19.93
14.77
12.00
10.54
% Of Sales
-
3.40%
3.49%
4.19%
4.01%
3.53%
3.03%
3.98%
3.09%
3.14%
3.37%
Manufacturing Exp.
-
160.38
142.69
130.01
103.21
87.60
75.53
39.18
32.32
25.17
24.22
% Of Sales
-
8.88%
9.14%
10.45%
8.64%
7.69%
6.89%
7.82%
6.75%
6.59%
7.75%
General & Admin Exp.
-
21.39
14.24
12.22
12.81
10.98
10.48
4.86
4.95
3.80
3.14
% Of Sales
-
1.18%
0.91%
0.98%
1.07%
0.96%
0.96%
0.97%
1.03%
0.99%
1.01%
Selling & Distn. Exp.
-
59.46
37.51
34.00
31.16
27.82
28.99
16.21
14.47
11.69
9.99
% Of Sales
-
3.29%
2.40%
2.73%
2.61%
2.44%
2.64%
3.24%
3.02%
3.06%
3.20%
Miscellaneous Exp.
-
6.88
3.11
4.24
5.71
4.42
2.45
1.27
1.71
0.89
9.99
% Of Sales
-
0.38%
0.20%
0.34%
0.48%
0.39%
0.22%
0.25%
0.36%
0.23%
0.53%
EBITDA
437.10
265.52
210.91
201.87
190.49
179.82
172.37
69.18
82.46
66.45
45.75
EBITDA Margin
20.29%
14.70%
13.51%
16.23%
15.94%
15.78%
15.71%
13.81%
17.23%
17.39%
14.65%
Other Income
4.52
1.48
2.41
1.05
4.00
0.00
0.65
0.16
0.63
0.52
1.85
Interest
22.96
37.42
43.51
38.36
40.02
48.02
42.28
17.12
18.66
26.45
14.48
Depreciation
49.87
48.75
42.56
40.06
38.46
36.53
31.02
19.11
17.03
14.48
13.02
PBT
369.01
180.82
127.26
124.50
116.01
95.27
99.72
33.11
47.40
26.04
20.09
Tax
88.61
43.89
41.27
42.20
34.21
26.55
22.47
9.61
18.96
8.47
5.28
Tax Rate
24.01%
23.69%
31.50%
33.90%
29.49%
27.87%
22.53%
29.02%
40.00%
32.53%
26.28%
PAT
280.40
141.40
89.75
82.31
81.80
68.72
77.25
23.50
28.06
16.71
14.08
PAT before Minority Interest
280.41
141.40
89.75
82.31
81.80
68.72
77.25
23.50
28.44
17.57
14.81
Minority Interest
0.01
0.00
0.00
0.00
0.00
0.00
0.00
0.00
-0.38
-0.86
-0.73
PAT Margin
13.01%
7.83%
5.75%
6.62%
6.84%
6.03%
7.04%
4.69%
5.86%
4.37%
4.51%
PAT Growth
98.29%
57.55%
9.04%
0.62%
19.03%
-11.04%
228.72%
-16.25%
67.92%
18.68%
 
EPS
30.09
15.17
9.63
8.83
8.78
7.37
8.29
2.52
3.01
1.79
1.51

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 11
Mar 10
Mar 09
Mar 08
Shareholder's Funds
652.49
543.45
455.43
400.13
357.40
308.15
163.16
146.45
123.45
111.53
Share Capital
23.30
23.58
23.58
23.86
24.22
24.22
12.11
12.11
11.71
11.71
Total Reserves
629.19
519.86
431.85
376.27
333.18
283.94
151.05
134.34
111.53
99.82
Non-Current Liabilities
299.31
321.06
312.31
296.59
243.78
211.03
290.20
209.85
210.70
233.12
Secured Loans
171.74
199.64
190.53
187.38
176.66
152.72
204.83
138.66
160.86
127.57
Unsecured Loans
8.57
8.57
12.17
14.17
14.57
10.75
62.65
50.16
31.35
89.58
Long Term Provisions
23.63
12.32
16.87
8.39
1.42
0.29
0.00
0.00
0.00
0.00
Current Liabilities
624.70
590.98
621.68
494.31
501.02
482.76
70.10
57.99
59.62
57.40
Trade Payables
329.55
242.63
258.73
196.97
184.90
166.72
65.30
50.18
54.78
54.50
Other Current Liabilities
132.83
82.94
56.42
51.00
43.80
41.53
1.77
1.68
1.33
0.80
Short Term Borrowings
157.73
263.25
305.64
244.66
258.41
252.43
0.00
0.00
0.00
0.00
Short Term Provisions
4.59
2.16
0.89
1.68
13.91
22.08
3.03
6.13
3.51
2.11
Total Liabilities
1,576.50
1,455.49
1,389.42
1,191.03
1,102.20
1,001.94
523.46
419.15
403.24
416.63
Net Block
643.81
624.86
602.39
581.09
493.42
448.46
247.84
208.20
205.24
189.94
Gross Block
1,030.97
970.09
909.20
848.13
725.47
685.21
393.33
332.42
309.85
277.70
Accumulated Depreciation
387.16
345.22
306.81
267.04
232.05
236.75
145.49
124.21
104.61
87.76
Non Current Assets
672.50
671.20
652.55
619.61
536.97
476.40
263.50
213.35
207.43
217.81
Capital Work in Progress
12.21
32.75
28.45
14.28
34.04
16.06
10.37
3.40
0.64
14.67
Non Current Investment
13.36
12.44
10.76
11.94
4.63
4.63
5.28
1.74
1.55
13.20
Long Term Loans & Adv.
3.12
1.15
10.95
12.30
4.88
7.24
0.00
0.00
0.00
0.00
Other Non Current Assets
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
904.00
784.29
736.86
571.42
565.23
525.54
259.96
205.81
195.80
198.80
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
325.40
246.61
278.21
209.63
178.35
164.20
91.83
64.41
60.52
66.21
Sundry Debtors
488.63
458.54
374.94
296.81
331.69
314.27
121.34
115.87
113.48
103.29
Cash & Bank
7.64
5.55
4.27
4.17
4.82
3.58
5.27
8.52
3.48
4.02
Other Current Assets
82.32
6.56
10.21
0.00
50.37
43.49
41.52
17.01
18.32
25.27
Short Term Loans & Adv.
75.50
67.02
69.23
60.81
50.37
43.49
40.62
16.01
17.52
24.49
Net Current Assets
279.30
193.31
115.19
77.11
64.20
42.78
189.86
147.82
136.18
141.39
Total Assets
1,576.50
1,455.49
1,389.41
1,191.03
1,102.20
1,001.94
523.46
419.16
403.23
416.65

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 11
Mar 10
Mar 09
Mar 08
Cash From Operating Activity
250.74
143.09
69.77
174.75
133.29
104.59
20.56
59.12
64.90
28.39
PBT
185.29
131.02
124.50
116.01
95.27
99.72
33.11
47.40
26.04
20.09
Adjustment
86.84
75.20
75.12
71.63
79.30
69.40
38.76
38.77
41.71
27.51
Changes in Working Capital
19.49
-33.49
-105.19
8.47
-21.25
-49.58
-40.22
-13.27
2.39
-15.17
Cash after chg. in Working capital
291.62
172.74
94.44
196.11
153.33
119.53
31.65
72.90
70.14
32.43
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-40.88
-29.64
-24.67
-21.36
-20.03
-14.94
-11.09
-13.80
-5.24
-4.05
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-33.21
-61.67
-73.54
-106.98
-98.79
-107.01
-76.36
-30.46
-11.51
-33.16
Net Fixed Assets
-49.10
-62.81
-72.64
-92.88
-46.34
-322.27
-65.29
-22.98
-19.64
-21.98
Net Investments
-1.46
-1.68
1.18
-7.30
-0.01
13.50
-3.23
0.00
12.15
-12.18
Others
17.35
2.82
-2.08
-6.80
-52.44
201.76
-7.84
-7.48
-4.02
1.00
Cash from Financing Activity
-215.41
-80.07
3.92
-68.23
-33.26
1.46
52.55
-23.62
-53.92
3.61
Net Cash Inflow / Outflow
2.13
1.35
0.15
-0.45
1.24
-0.95
-3.25
5.04
-0.53
-1.16
Opening Cash & Equivalents
4.64
3.29
3.15
3.60
3.58
4.53
8.52
3.48
4.02
5.18
Closing Cash & Equivalent
6.77
4.64
3.29
3.15
4.82
3.58
5.27
8.52
3.49
4.02

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 11
Mar 10
Mar 09
Mar 08
Book Value (Rs.)
70.01
57.61
48.28
41.93
36.90
31.81
16.84
15.12
13.16
11.90
ROA
9.33%
6.31%
6.38%
7.13%
6.53%
10.13%
4.99%
6.92%
4.29%
3.78%
ROE
23.65%
17.97%
19.24%
21.60%
20.65%
32.78%
15.18%
21.09%
14.97%
14.08%
ROCE
21.39%
17.01%
17.31%
18.50%
18.33%
23.93%
13.12%
20.30%
16.30%
11.03%
Fixed Asset Turnover
1.81
1.66
1.44
1.64
1.75
2.19
1.45
1.57
1.42
1.26
Receivable days
95.71
97.45
97.10
89.05
95.59
67.25
82.06
83.04
95.17
98.73
Inventory Days
57.80
61.36
70.52
54.97
50.69
39.52
54.05
45.23
55.64
69.71
Payable days
64.68
68.08
73.82
67.66
65.68
45.51
45.97
46.92
62.87
59.81
Cash Conversion Cycle
88.83
90.73
93.79
76.36
80.60
61.26
90.14
81.35
87.94
108.62
Total Debt/Equity
0.58
0.93
1.20
1.20
1.26
1.45
1.64
1.29
1.56
1.95
Interest Cover
5.95
4.01
4.25
3.90
2.98
3.36
2.93
3.54
1.98
2.39

News Update:


  • Aarti Drugs to consider share buyback proposal
    16th Mar 2021, 12:25 PM

    A meeting of the Board of Directors of the company is scheduled to be held on Friday, March 19, 2021, to consider the proposal of buyback

    Read More
  • Aarti Drugs closes subsidiary company
    20th Feb 2021, 10:04 AM

    The wounding-up of this subsidiary will not affect the revenue or business of the company due to nil business activity of this subsidiary

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.